Provided by Tiger Trade Technology Pte. Ltd.

Entrada Therapeutics, Inc.

7.30
+0.23003.25%
Post-market: 7.300.00000.00%19:30 EDT
Volume:306.54K
Turnover:2.20M
Market Cap:283.39M
PE:-1.84
High:7.34
Open:7.07
Low:6.96
Close:7.07
52wk High:16.45
52wk Low:5.02
Shares:38.82M
Float Shares:22.56M
Volume Ratio:1.23
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9676
EPS(LYR):-3.4746
ROE:-54.09%
ROA:-29.20%
PB:1.21
PE(LYR):-2.10

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise

Reuters
·
May 08

Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst

TIPRANKS
·
May 08

Entrada Therapeutics Shares Slump 61% to $6.05 After Co's Duchenne Drug Misses Expectations in Trial

THOMSON REUTERS
·
May 07

Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)

TIPRANKS
·
May 07

Entrada shares sink after Duchenne drug falls short of expectations

Reuters
·
May 07

Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data

TIPRANKS
·
May 07

Entrada Therapeutics posts corporate presentation outlining 2026 clinical milestones for DMD, DM1 programs

Reuters
·
May 07

Entrada Therapeutics Q1 EPS $(0.95) Beats $(1.09) Estimate, Sales $875.000K Miss $1.393M Estimate

Benzinga Earnings
·
May 07

Entrada Therapeutics Shares Down 27% Premarket After Co Reports Duchenne Drug Trial Data, Q1 Results

THOMSON REUTERS
·
May 07

Entrada Therapeutics Q1 net loss beats analyst estimates

Reuters
·
May 07

Entrada Therapeutics, Inc. Q1 Income From Operations USD -42.303 Million

THOMSON REUTERS
·
May 07

Press Release: Entrada Therapeutics Reports First Quarter 2026 Financial Results

Dow Jones
·
May 07

Entrada's Duchenne drug shown to improve muscle function in early trial

Reuters
·
May 07

Entrada Therapeutics: Cohort 1 of Phase 1/2 Elevate-44-201 Study Achieved Primary Objective With Favorable Safety and Tolerability

THOMSON REUTERS
·
May 07

Entrada Therapeutics: Statistically Significant & Potentially Differentiated Improvement in Treated Participants VS Placebo in Time to Rise Velocity

THOMSON REUTERS
·
May 07

Entrada Therapeutics: Cohort 1 Showed 2.31% Increase in Exon Skipping Over 2.66% Baseline in Treated Participants

THOMSON REUTERS
·
May 07

Entrada Therapeutics: Initiated Dosing of Elevate-44-201 Cohort 2 at Increased Dose of 12 Mg/Kg, on Track to Report Data by Year-End 2026

THOMSON REUTERS
·
May 07

Entrada Therapeutics: Cohort 1 Showed 2.36% Increase in Dystrophin Over 4.00% Baseline in Treated Participants

THOMSON REUTERS
·
May 07

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

GlobeNewswire
·
May 07

Entrada R&D President Sethuraman Natarajan sells 25,907 shares worth $398,684.79

Reuters
·
May 05